Provided by Tiger Fintech (Singapore) Pte. Ltd.

3SBIO

30.000
-0.140-0.46%
Volume:29.46M
Turnover:881.84M
Market Cap:72.96B
PE:31.86
High:30.600
Open:30.340
Low:29.600
Close:30.140
52wk High:36.800
52wk Low:5.426
Shares:2.43B
HK Float Shares:2.43B
Volume Ratio:1.05
T/O Rate:1.21%
Dividend:0.25
Dividend Rate:0.83%
EPS(LYR):0.942
ROE:13.95%
ROA:6.19%
PB:4.09
PE(LYR):31.86
PS:7.36

Loading ...

3SBio Inc. Reports 0.8% Decline in Revenue, Net Profit Up 24.6% for First Half of 2025

Reuters
·
Yesterday

China Merchants International: Limited Impact Expected from US Tariffs on Innovative Drugs for CXO Companies, Recommends Buying 3SBIO (01530) and Others

Stock News
·
Yesterday

BOCOM International: Trump's Drug Tariffs Have Limited Impact on Chinese Pharmaceuticals, Recommends Focus on AKESO (09926) and Others

Stock News
·
Sep 29

Innovative Drug Industry Trend Established, Advancing Global Commercialization

Stock News
·
Sep 24

Is There More Room for 3SBio After Its 431% Surge and Recent Earnings Release?

Simply Wall St.
·
Sep 24

Is 3SBio (SEHK:1530) Undervalued? A Fresh Look at Its Recent Share Price Swings and Valuation

Simply Wall St.
·
Sep 22

Hong Kong Stock Concept Tracking | FTSE Russell Index Adjustments to Take Effect Soon! Multiple Strong Performers Lead New Growth Cycle (With Concept Stocks)

Stock News
·
Sep 19

Assessing 3SBio’s Share Price After 482% Rally and Recent Regulatory Updates

Simply Wall St.
·
Sep 14

China Securities Co., Ltd.: Innovative Drug Globalization Drives Pharmaceutical Industry Chain Recovery

Stock News
·
Sep 13

GF Securities: Industry's Medium to Long-term Positive Trend Established, BD Deals Are Just the Starting Point of This Round of Innovative Drug Value Revaluation

Stock News
·
Sep 10

BioNTech, Bristol Myers Say Read-Out Confirms Dose Selection for the Ongoing Pivotal Phase Iii Rosetta Lung-01 Trial

THOMSON REUTERS
·
Sep 08

BioNTech, Bristol Myers Squibb Say Bnt327 Plus Chemotherapy Shows Encouraging Antitumor Activity in Patients With Extensive-Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

BioNTech, Bristol Myers Say Interim Phase Ii Data Showed a 76.3% Confirmed Objective Response Rate, 100% Disease Control Rate

THOMSON REUTERS
·
Sep 08

China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others

Stock News
·
Sep 08

Huatai Asset Management Increases Stake in 3SBIO (01530) by 2.092 Million Shares at HK$31.18 Per Share

Stock News
·
Sep 05

HK Movers|Pharma Stocks Jumped. 3S Bio up 15%; Laekna up 8%; Junshi up 7%; HBM, SKB Bio and TigerMed up 6%.

Tiger Newspress
·
Sep 05

Stock Track | 3SBIO Soars 10.81% as Innovative Drug Stocks Rally Ahead of World Lung Cancer Congress

Stock Track
·
Sep 05

Hong Kong Stock Movement | Innovative Drug Stocks Rise Across the Board as 2025 World Lung Cancer Congress Approaches, Institutions Bullish on Valuation Recovery Potential of Innovative Drug Sector

Stock News
·
Sep 05

CMB International Slightly Lowers 3SBIO Target Price to HK$37.58, Maintains Buy Rating

Stock News
·
Sep 03

Hong Kong Stock Alert | 3SBIO (01530) Surges Over 3% Again as Institutions Highlight Project 707 Global Clinical Trial Launch as Key Profit Catalyst

Stock News
·
Sep 03